BlackRock has been building its iBonds target-maturity franchise for well over a decade, and shows no sign of stopping. The concept is structurally simple: each fund holds a basket of bonds that all mature in the same target year, pays out income along the way, then winds itself down and returns principal. You buy it, you wait, you get your money back plus whatever yield the market offered you at entry. It is, mechanically speaking, a bond. A bond in an ETF wrapper, for investors who find individual bonds operationally inconvenient but still, fundamentally, want a bond. BlackRock has turned this observation into a multi-billion-dollar franchise, which says something either about the elegance of the idea or the operational inconvenience of individual bonds.
Five new rungs were added today, all on the NYSE. IBMU and IBMV cover municipal bonds maturing in 2032 and 2033, offering tax-advantaged income to investors prepared to commit to the timeline. IBHM offers a 2033 high-yield and income option, for those who want their defined maturity with a meaningful credit spread attached. IBCB extends the investment-grade corporate ladder to 2036. IBIM does the same for inflation-protected securities, for investors who would like to know exactly when they will get their money back and whether it will still be worth something by then. Four asset classes, five tickers, and somewhere at BlackRock, a product manager quietly advancing the spreadsheet by one year.
In a product landscape otherwise distinguished by its ambition, there is something almost restful about this. The iBonds do what they say they will do. In this industry, that is not nothing.
Private equity has spent decades cultivating its mystique. The locked-up capital. The long horizons. The opacity. The whispered returns. The whole appeal is, at least in part, that it is categorically not like other investing. You commit your money for years. You have limited visibility into what it is worth in the interim. You collect, eventually, a premium that is either compensation for the illiquidity or an artefact of smoothed valuations, depending on which academic you ask.
LQPE would like to offer you a version of that experience, daily. It is an actively managed ETF holding between 250 and 350 public securities chosen because they exhibit characteristics of the kinds of companies PE funds typically target, with a derivatives overlay to replicate the leverage PE funds typically apply. It lists on the NYSE. The expense ratio is 1.25%. You can be out of it before lunch.
What you are buying, then, is private equity's aesthetic applied to a portfolio of public companies, with full ETF liquidity. This is either a genuinely interesting attempt to give ordinary investors access to a return profile historically reserved for large institutions, or it is a very elaborate route to something resembling the public equity market. Possibly both. The fund exists and is operational, which already puts it ahead of several ideas that have been described to me at conferences.
A semiconductor fund from one of China's larger asset managers, listed on the Hong Kong Stock Exchange under the ticker 3486. The timing is not subtle. Every government on the planet has recently decided that semiconductor supply chains are a matter of national survival, and has responded by subsidising, restricting, or politically weaponising them accordingly. Into this environment, a Chinese asset manager has listed a semiconductor ETF in Hong Kong, tracking companies involved in the design, manufacture, and packaging of chips across Asia, at a moment when the gap between regional ambition and regional capability in that sector remains one of the more consequential open questions in global technology.
Whether that makes it a compelling investment or a geopolitical statement or both is, as ever, left to the market.
Not the Nasdaq-100. Not the NYSE Composite. The NYSE 100, tracking the 100 largest non-financial companies listed on the New York Stock Exchange, which you will be forgiven for not having had strong views about until now.
It comes in two flavours: NYSX on the NYSE for US investors, and NYSX on the Toronto Stock Exchange for Canadian investors who would like the same exposure in a domestically-regulated wrapper. The ticker itself is a small masterpiece of nominal efficiency. A fund tracking the NYSE, carrying the ticker NYSX, listed on the NYSE. Whoever named it is either very literal or very pleased with themselves. Possibly both.
The NYSE 100 tilts toward industrials, healthcare, energy, and materials rather than technology. It is, in effect, a large-cap US benchmark for investors who feel that the Nasdaq-100 has become somewhat dominated by a small number of very large technology companies, which is a polite way of describing something that is also just factually true. Whether avoiding that concentration is wisdom or stubbornness depends entirely on what those companies do next.